Nature Biotechnology23, 1037 - 1039 (2005)
Published online: 31 August 2005; | doi:10.1038/nbt0905-1037
The problem with potency
Christopher Thomas Scott
San Francisco
Industry hopes to build on recent successes of monoclonal antibodies in oncology and inflammatory disease. But evidence is mounting that the exquisite selectivity and binding capacity of these therapeutics can have unwanted side effects, particularly in autoimmune disease. Christopher Thomas Scott investigates.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
